158 related articles for article (PubMed ID: 30873755)
1. Anti-cancer targets of formononetin and molecular mechanisms in osteosarcoma: Findings of bioinformatic and experimental assays.
Hu W; Wu X; Tang J; Zhao G; Xiao N; Zhang L; Li S
J Cell Mol Med; 2019 May; 23(5):3505-3511. PubMed ID: 30873755
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo studies of antiosteosarcoma activities of formononetin.
Hu W; Wu X; Tang J; Xiao N; Zhao G; Zhang L; Ou L
J Cell Physiol; 2019 Aug; 234(10):17305-17313. PubMed ID: 30790283
[TBL] [Abstract][Full Text] [Related]
3. Anticancer targets and mechanisms of calycosin to treat nasopharyngeal carcinoma.
Liu F; Pan Q; Wang L; Yi S; Liu P; Huang W
Biofactors; 2020 Jul; 46(4):675-684. PubMed ID: 32449282
[TBL] [Abstract][Full Text] [Related]
4. Integrative findings indicate anti-tumor biotargets and molecular mechanisms of calycosin against osteosarcoma.
Tan J; Qin X; Liu B; Mo H; Wu Z; Yuan Z
Biomed Pharmacother; 2020 Jun; 126():110096. PubMed ID: 32179199
[TBL] [Abstract][Full Text] [Related]
5. Clinical case report of patients with osteosarcoma and anticancer benefit of calycosin against human osteosarcoma cells.
Qiu R; Ma G; Li X; Shi Q; Li X; Zhou X; Tang Y; Xie Z; Liao S; Qin Y; Wang R; Ye Y; Luo J; Zhang J
J Cell Biochem; 2019 Jun; 120(6):10697-10706. PubMed ID: 30652346
[TBL] [Abstract][Full Text] [Related]
6. Formononetin induces apoptosis of human osteosarcoma cell line U2OS by regulating the expression of Bcl-2, Bax and MiR-375 in vitro and in vivo.
Hu W; Xiao Z
Cell Physiol Biochem; 2015; 37(3):933-9. PubMed ID: 26381132
[TBL] [Abstract][Full Text] [Related]
7. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
8. Calycosin, a Phytoestrogen Isoflavone, Induces Apoptosis of Estrogen Receptor-Positive MG-63 Osteosarcoma Cells via the Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Sun H; Yin M; Qian W; Yin H
Med Sci Monit; 2018 Sep; 24():6178-6186. PubMed ID: 30182951
[TBL] [Abstract][Full Text] [Related]
9. Anti-neoplastic characteristics and potential targets of calycosin against bisphenol A-related osteosarcoma: bioinformatics analysis.
Pan Q; Wu K; Tan J; Li Y; Liang X; Su M
Bioengineered; 2021 Dec; 12(1):4278-4288. PubMed ID: 34311656
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
[TBL] [Abstract][Full Text] [Related]
11. Antineoplastic effect of calycosin on osteosarcoma through inducing apoptosis showing in vitro and in vivo investigations.
Qiu R; Ma G; Zheng C; Qiu X; Li X; Li X; Mo J; Li Z; Liu Y; Mo L; Bi G; Ye Y
Exp Mol Pathol; 2014 Aug; 97(1):17-22. PubMed ID: 24797937
[TBL] [Abstract][Full Text] [Related]
12. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
13. Theabrownin triggers DNA damage to suppress human osteosarcoma U2OS cells by activating p53 signalling pathway.
Jin W; Zhou L; Yan B; Yan L; Liu F; Tong P; Yu W; Dong X; Xie L; Zhang J; Xu Y; Li C; Yuan Q; Shan L; Efferth T
J Cell Mol Med; 2018 Sep; 22(9):4423-4436. PubMed ID: 29993186
[TBL] [Abstract][Full Text] [Related]
14. Activation of Estrogen Receptor Alpha by Decitabine Inhibits Osteosarcoma Growth and Metastasis.
Lillo Osuna MA; Garcia-Lopez J; El Ayachi I; Fatima I; Khalid AB; Kumpati J; Slayden AV; Seagroves TN; Miranda-Carboni GA; Krum SA
Cancer Res; 2019 Mar; 79(6):1054-1068. PubMed ID: 30593524
[TBL] [Abstract][Full Text] [Related]
15. Osteosarcoma Pathogenesis Leads the Way to New Target Treatments.
Fernandes I; Melo-Alvim C; Lopes-Brás R; Esperança-Martins M; Costa L
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467481
[TBL] [Abstract][Full Text] [Related]
16. Anti-cancer targets and molecular mechanisms of formononetin in treating osteosarcoma based on network pharmacology.
Chen L; Zhou Y; Weng Z; Liu S; Li T; Wang Y; Yang Y; Liu H; Huang W
Aging (Albany NY); 2023 Oct; 15(20):11489-11507. PubMed ID: 37870753
[TBL] [Abstract][Full Text] [Related]
17. Anti-Colorectal Cancer Mechanisms of Formononetin Identified by Network Pharmacological Approach.
Zhang L; Gong Y; Wang S; Gao F
Med Sci Monit; 2019 Oct; 25():7709-7714. PubMed ID: 31608899
[TBL] [Abstract][Full Text] [Related]
18. PLK2 modulation of enriched TAp73 affects osteogenic differentiation and prognosis in human osteosarcoma.
Li W; Zhang X; Xi X; Li Y; Quan H; Liu S; Wu L; Wu P; Lan W; Shao Y; Li H; Chen K; Hu Z
Cancer Med; 2020 Jun; 9(12):4371-4385. PubMed ID: 32349184
[TBL] [Abstract][Full Text] [Related]
19. Tetramethylpyrazine inhibits osteosarcoma cell proliferation via downregulation of NF-κB in vitro and in vivo.
Wang Y; Fu Q; Zhao W
Mol Med Rep; 2013 Oct; 8(4):984-8. PubMed ID: 23912183
[TBL] [Abstract][Full Text] [Related]
20. Bioinformatic and experimental data decipher the pharmacological targets and mechanisms of plumbagin against hepatocellular carcinoma.
Zhou R; Wu K; Su M; Li R
Environ Toxicol Pharmacol; 2019 Aug; 70():103200. PubMed ID: 31158732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
